TP53 and myelodysplastic syndrome: <h4>Background</h4>The recent fifth edition of World Health Organization and International Consensus Classification in 2022 recognized TP53-mutated myelodysplastic neoplasms (MDS) as a distinct entity requiring multi-hit classification.